# Immatics N.V. (IMTX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.08, market value $1.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Immatics N.V. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 23.1×**. Each dollar of revenue is priced at 23.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -21.8%** (5-yr avg -6.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -543.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: -40.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -36.7%**. Each dollar of assets produces -36.7% of profit.

## Growth
- **EPS growth (1 yr): -1250.0%**. Earnings per share fell 1250.0%.

## Financial health
- **Interest coverage: -261.3×**. Operating profit covers interest only -261.3×: fragile.
- **Current ratio: 11.72** (quick 11.72). Current assets cover the next year's liabilities 11.72 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Immatics N.V. does not currently pay a dividend, but it returned -13.5% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Immatics N.V.; the consensus is strong_buy, with an average price target of $16.40 (+132% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -30.7%** (YTD -32.8%, 3-mo -21.7%). The shares are down 30.7% over twelve months including dividends.
- **From 52-week high: -43.0%** (6.4% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 1.49** (volatility 57%). Beta of 1.49 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IMTX · Page: https://foliofundamentals.com/stocks/imtx

Not investment advice.